异基因造血干细胞移植后残留莫加莫珠单抗浓度下的严重移植物抗宿主病 - Suppr

Severe graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with residual mogamulizumab concentration.

作者信息

Hosoi Hiroki, Mushino Toshiki, Nishikawa Akinori, Hashimoto Hisako, Murata Shogo, Hatanaka Kazuo, Tamura Shinobu, Hanaoka Nobuyuki, Shimizu Norio, Sonoki Takashi

机构信息

Hematology/Oncology, Wakayama Medical University, Kimiidera 811-1, Wakayama, 641-8510, Japan.

Department of Cell Therapy, Institute of Biomedical Research and Innovation, 2-2, Minatojima-Minamimachi, Chuo-ku, Kobe, 650-0047, Japan.

出版信息

Int J Hematol. 2018 Jun;107(6):717-719. doi: 10.1007/s12185-018-2456-9. Epub 2018 Apr 18.

DOI:10.1007/s12185-018-2456-9

PMID:29671245

Abstract

摘要

相似文献

Severe graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with residual mogamulizumab concentration.

Int J Hematol. 2018 Jun;107(6):717-719. doi: 10.1007/s12185-018-2456-9. Epub 2018 Apr 18.

Plasma exchange eliminates residual mogamulizumab but does not warrant prompt recovery of peripheral Treg levels.

Transfus Apher Sci. 2019 Aug;58(4):472-474. doi: 10.1016/j.transci.2019.05.011. Epub 2019 Jul 9.

Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation.

Bone Marrow Transplant. 2019 Feb;54(2):338-342. doi: 10.1038/s41409-018-0291-5. Epub 2018 Aug 16.

Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1608-1614. doi: 10.1016/j.bbmt.2016.05.017. Epub 2016 May 21.

Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation.

Int J Hematol. 2022 Mar;115(3):435-439. doi: 10.1007/s12185-021-03250-3. Epub 2021 Oct 27.

Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation.

Int J Hematol. 2013 Aug;98(2):258-60. doi: 10.1007/s12185-013-1387-8. Epub 2013 Jun 26.

Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality.

J Clin Oncol. 2016 Oct 1;34(28):3426-33. doi: 10.1200/JCO.2016.67.8250. Epub 2016 Aug 9.

Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation.

Br J Haematol. 2019 Feb;184(3):479-483. doi: 10.1111/bjh.15123. Epub 2018 Feb 7.

HLA-haploidentical hematopoietic stem cell transplantation with low-dose thymoglobulin GVHD prophylaxis for an adult T cell leukemia/lymphoma patient treated with pretransplant mogamulizumab.

Ann Hematol. 2017 Feb;96(2):327-328. doi: 10.1007/s00277-016-2856-y. Epub 2016 Oct 21.

Successful treatment with mogamulizumab followed by allogeneic hematopoietic stem-cell transplantation in adult T-cell leukemia/lymphoma: a report of two cases.

Int J Hematol. 2016 Dec;104(6):744-748. doi: 10.1007/s12185-016-2087-y. Epub 2016 Aug 29.

引用本文的文献

Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.

Int J Mol Sci. 2024 Feb 12;25(4):2203. doi: 10.3390/ijms25042203.

Monoclonal Antibodies in Dermatooncology-State of the Art and Future Perspectives.

Cancers (Basel). 2019 Sep 24;11(10):1420. doi: 10.3390/cancers11101420.

Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma.

Onco Targets Ther. 2019 Feb 7;12:1085-1094. doi: 10.2147/OTT.S165615. eCollection 2019.

本文引用的文献

Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance.

Int J Hematol. 2017 Oct;106(4):522-532. doi: 10.1007/s12185-017-2270-9. Epub 2017 Jun 9.

Successful treatment with mogamulizumab followed by allogeneic hematopoietic stem-cell transplantation in adult T-cell leukemia/lymphoma: a report of two cases.

Int J Hematol. 2016 Dec;104(6):744-748. doi: 10.1007/s12185-016-2087-y. Epub 2016 Aug 29.

J Clin Oncol. 2016 Oct 1;34(28):3426-33. doi: 10.1200/JCO.2016.67.8250. Epub 2016 Aug 9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Severe graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with residual mogamulizumab concentration.

作者信息

Hosoi Hiroki, Mushino Toshiki, Nishikawa Akinori, Hashimoto Hisako, Murata Shogo, Hatanaka Kazuo, Tamura Shinobu, Hanaoka Nobuyuki, Shimizu Norio, Sonoki Takashi

机构信息

Hematology/Oncology, Wakayama Medical University, Kimiidera 811-1, Wakayama, 641-8510, Japan.

Department of Cell Therapy, Institute of Biomedical Research and Innovation, 2-2, Minatojima-Minamimachi, Chuo-ku, Kobe, 650-0047, Japan.

出版信息

Int J Hematol. 2018 Jun;107(6):717-719. doi: 10.1007/s12185-018-2456-9. Epub 2018 Apr 18.

DOI:10.1007/s12185-018-2456-9

PMID:29671245

Abstract

摘要

Severe graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with residual mogamulizumab concentration.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Severe graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with residual mogamulizumab concentration.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献